NCT05880849View on ClinicalTrials.gov

Choline Effects - Pre-symptomatic AD

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

Choline

Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days

Trial Locations (1)

77054

The University of Texas Health Science Center at Houston (UTHealth), Houston

Sponsors

Collaborators (1)

Balchem Corporation

All Listed Sponsors

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Massachusetts Institute of Technology

OTHER

collaborator

Balchem Corporation

INDUSTRY

lead

Paul E Schulz

OTHER

NCT05880849 - Choline Effects - Pre-symptomatic AD | Biotech Hunter | Biotech Hunter